Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $120
10/19/2026
Impact: 50
Healthcare
Piper Sandler analyst Biren Amin has maintained an Overweight rating on BridgeBio Pharma (NASDAQ: BBIO) and increased the price target from $115 to $120.
AI summary, not financial advice
Share: